Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation.
BACKGROUND
Obesity is a significant risk factor for psoriasis and body mass index (BMI) correlates with disease severity. Objectives To investigate the relationship between obesity and psoriasis, focusing on the role of adipokines such as leptin and resistin.


METHODS
Patients with psoriasis (n = 30) were recruited and their BMI, waist circumference and disease severity [Psoriasis Area and Severity Index (PASI)] were recorded. Fasting serum samples were obtained on enrolment and after a course of ultraviolet (UV) B treatment. Age-, sex- and BMI-matched healthy controls were also recruited.


RESULTS
On enrolment, serum leptin and soluble leptin receptor levels were not raised compared with the controls. However, resistin, interleukin (IL)-1beta, IL-6, and chemokines CCL2, CXCL8 and CXCL9 were all significantly elevated in the patient group and serum resistin correlated with disease severity (r = 0.372, P = 0.043). Improvement after UVB treatment was accompanied by decreased serum CXCL8. In vitro, both leptin and resistin could induce CXCL8 and tumour necrosis factor-alpha production by blood monocytes, and leptin could additionally induce IL-1beta and IL-1 receptor antagonist production. Leptin also dose dependently increased secretion of the growth factor amphiregulin by ex vivo-cultured lesional psoriasis skin.


CONCLUSIONS
These data support the view that leptin and resistin may be involved in the pathogenesis of psoriasis in overweight individuals, possibly by augmenting the cytokine expression by the inflammatory infiltrate.
Johnston
A
A
Department of Immunology, Landspitali University Hospital, Reykjavik, Iceland.
Arnadottir
S
S
Gudjonsson
J E
JE
Aphale
A
A
Sigmarsdottir
A A
AA
Gunnarsson
S I
SI
Steinsson
J T
JT
Elder
J T
JT
Valdimarsson
H
H
D054392:Adipokines / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D066258:Amphiregulin; D001824:Body Constitution; D015992:Body Mass Index; D002908:Chronic Disease; D016207:Cytokines / Q000096:biosynthesis / Q000097:blood; D015536:Down-Regulation; D066255:EGF Family of Proteins; D005260:Female; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D020738:Leptin / Q000097:blood* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000378:metabolism; D011565:Psoriasis / Q000209:etiology* / Q000378:metabolism / Q000532:radiotherapy; D054411:Receptors, Leptin / Q000378:metabolism; D052243:Resistin / Q000097:blood*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D046509:Tissue Culture Techniques; D014467:Ultraviolet Therapy
C587848:AREG protein, human; D054392:Adipokines; D066258:Amphiregulin; D016207:Cytokines; D066255:EGF Family of Proteins; D006023:Glycoproteins; D018836:Inflammation Mediators; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D054411:Receptors, Leptin; D052243:Resistin